Lexeo Therapeutics Files 8-K: Material Agreement & Equity Sales
Ticker: LXEO · Form: 8-K · Filed: May 27, 2025 · CIK: 1907108
| Field | Detail |
|---|---|
| Company | Lexeo Therapeutics, Inc. (LXEO) |
| Form Type | 8-K |
| Filed Date | May 27, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
Related Tickers: LXEO
TL;DR
Lexeo Therapeutics (LXEO) filed an 8-K on 5/27, reporting a material definitive agreement and unregistered equity sales.
AI Summary
Lexeo Therapeutics, Inc. announced on May 27, 2025, that it entered into a material definitive agreement. The company also disclosed unregistered sales of equity securities and provided a Regulation FD disclosure. This filing includes financial statements and exhibits related to these events.
Why It Matters
This 8-K filing indicates significant corporate activity for Lexeo Therapeutics, including a new material agreement and equity transactions, which could impact its financial standing and strategic direction.
Risk Assessment
Risk Level: medium — The filing details a material definitive agreement and unregistered equity sales, which can introduce financial and regulatory risks.
Key Numbers
- 001-41855 — SEC File Number (Identifies Lexeo Therapeutics' filing with the SEC.)
- 85-4012572 — IRS Employer Identification No. (Tax identification number for Lexeo Therapeutics.)
Key Players & Entities
- Lexeo Therapeutics, Inc. (company) — Registrant
- May 27, 2025 (date) — Date of earliest event reported
- 345 Park Avenue South, Floor 6 (location) — Principal Executive Offices
- New York, New York (location) — Principal Executive Offices
- 10010 (location) — Principal Executive Offices Zip Code
FAQ
What is the nature of the material definitive agreement entered into by Lexeo Therapeutics?
The filing states that Lexeo Therapeutics entered into a 'Material Definitive Agreement' but does not provide specific details about the agreement's terms or counterparty in the provided text.
What type of equity securities were sold unregistered by Lexeo Therapeutics?
The filing mentions 'Unregistered Sales of Equity Securities' but does not specify the type or amount of equity securities sold in the provided text.
What is the purpose of the Regulation FD Disclosure mentioned in the filing?
Regulation FD (Fair Disclosure) ensures that material non-public information is disclosed to all investors simultaneously, suggesting this filing may contain such information.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on May 27, 2025.
Where are Lexeo Therapeutics' principal executive offices located?
Lexeo Therapeutics' principal executive offices are located at 345 Park Avenue South, Floor 6, New York, New York, 10010.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 27, 2025 regarding Lexeo Therapeutics, Inc. (LXEO).